BACKGROUND: The discovery that purine nucleoside phosphorylase (PNP) deficiency leads to T-cell lymphopenia was the basis for introducing PNP inhibitors for T-cell leukemias. Forodesine is an orally bioavailable PNP inhibitor with picomolar potency. Because T lymphoblasts and indolent chronic lymphocytic leukemia (CLL) B cells inherently elicit favorable pharmacokinetics to accumulate deoxyguanosine triphosphate (dGTP), forodesine demonstrated promising activity in preclinical and clinical settings for patients with T-cell acute lymphoblastic leukemia (T-ALL) and B-cell CLL (B-CLL). However, the use of forodesine in B-cell ALL (B-ALL) is unknown. PATIENTS AND METHODS: Leukemic blasts obtained from pediatric patients with de novo B-ALL (n = 10) were incubated with forodesine and deoxyguanosine (dGuo), and the biological end points of apoptosis, intracellular dGTP accumulation, and inhibition of RNA and DNA synthesis were measured. Additionally, adult patients with B-ALL (n = 2) were intravenously infused with 80 mg/m(2)/d daily for 5 days. After therapy, clinical response, toxicity, laboratory biomarkers including PNP enzyme inhibition, and plasma forodesine, dGuo, and intracellular dGTP levels were analyzed. RESULTS: Our in vitro investigations demonstrated that forodesine treatment inhibited proliferation and induced modest apoptosis in de novo B-ALL lymphoblasts. There was time-dependent accumulation of dGTP and inhibition of RNA and DNA synthesis. During therapy, neither patient achieved a complete response (CR), but there was disease stabilization for several weeks in both patients. There was significant maintained inhibition of PNP enzyme in red blood cells, accumulation of forodesine and dGuo in plasma, and intracellular dGTP accumulation in both patients. CONCLUSION: Our preclinical and clinical investigations suggest that forodesine has activity in B-ALL. However, it needs to be either infused with dGuo or combined with established chemotherapeutic agents based on mechanistic rationale.
BACKGROUND: The discovery that purine nucleoside phosphorylase (PNP) deficiency leads to T-cell lymphopenia was the basis for introducing PNP inhibitors for T-cell leukemias. Forodesine is an orally bioavailable PNP inhibitor with picomolar potency. Because T lymphoblasts and indolent chronic lymphocytic leukemia (CLL) B cells inherently elicit favorable pharmacokinetics to accumulate deoxyguanosine triphosphate (dGTP), forodesine demonstrated promising activity in preclinical and clinical settings for patients with T-cell acute lymphoblastic leukemia (T-ALL) and B-cell CLL (B-CLL). However, the use of forodesine in B-cell ALL (B-ALL) is unknown. PATIENTS AND METHODS: Leukemic blasts obtained from pediatric patients with de novo B-ALL (n = 10) were incubated with forodesine and deoxyguanosine (dGuo), and the biological end points of apoptosis, intracellular dGTP accumulation, and inhibition of RNA and DNA synthesis were measured. Additionally, adult patients with B-ALL (n = 2) were intravenously infused with 80 mg/m(2)/d daily for 5 days. After therapy, clinical response, toxicity, laboratory biomarkers including PNP enzyme inhibition, and plasma forodesine, dGuo, and intracellular dGTP levels were analyzed. RESULTS: Our in vitro investigations demonstrated that forodesine treatment inhibited proliferation and induced modest apoptosis in de novo B-ALL lymphoblasts. There was time-dependent accumulation of dGTP and inhibition of RNA and DNA synthesis. During therapy, neither patient achieved a complete response (CR), but there was disease stabilization for several weeks in both patients. There was significant maintained inhibition of PNP enzyme in red blood cells, accumulation of forodesine and dGuo in plasma, and intracellular dGTP accumulation in both patients. CONCLUSION: Our preclinical and clinical investigations suggest that forodesine has activity in B-ALL. However, it needs to be either infused with dGuo or combined with established chemotherapeutic agents based on mechanistic rationale.
Authors: V Gandhi; W Plunkett; S Weller; M Du; M Ayres; C O Rodriguez; P Ramakrishna; G L Rosner; J P Hodge; S O'Brien; M J Keating Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: J Kurtzberg; T J Ernst; M J Keating; V Gandhi; J P Hodge; D F Kisor; J J Lager; C Stephens; J Levin; T Krenitsky; G Elion; B S Mitchell Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: Carlos O Rodriguez; Beverly S Mitchell; Mary Ayres; Staffan Eriksson; Varsha Gandhi Journal: Cancer Res Date: 2002-06-01 Impact factor: 12.701
Authors: G A Kicska; L Long; H Hörig; C Fairchild; P C Tyler; R H Furneaux; V L Schramm; H L Kaufman Journal: Proc Natl Acad Sci U S A Date: 2001-04-03 Impact factor: 11.205
Authors: P Bader; J Hancock; H Kreyenberg; N J Goulden; D Niethammer; A Oakhill; C G Steward; R Handgretinger; J F Beck; T Klingebiel Journal: Leukemia Date: 2002-09 Impact factor: 11.528
Authors: V Gandhi; W Plunkett; C O Rodriguez; B J Nowak; M Du; M Ayres; D F Kisor; B S Mitchell; J Kurtzberg; M J Keating Journal: J Clin Oncol Date: 1998-11 Impact factor: 44.544
Authors: Gary B Evans; Scott A Cameron; Andreas Luxenburger; Rong Guan; Javier Suarez; Keisha Thomas; Vern L Schramm; Peter C Tyler Journal: Bioorg Med Chem Date: 2015-07-30 Impact factor: 3.641
Authors: Tamara Davenne; Jenny Klintman; Sushma Sharma; Rachel E Rigby; Henry T W Blest; Chiara Cursi; Anne Bridgeman; Bernadeta Dadonaite; Kim De Keersmaecker; Peter Hillmen; Andrei Chabes; Anna Schuh; Jan Rehwinkel Journal: Cell Rep Date: 2020-05-12 Impact factor: 9.423